Does cannabis fuel aggressive lung cancer in young adults?
NCT ID NCT05119244
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is investigating how common cannabis use is among lung cancer patients under 60 and whether it is linked to more aggressive tumors. Researchers will collect blood and hair samples from 150 participants across three French hospitals. The goal is to better understand if cannabis plays a role in lung cancer development and progression, especially in younger people.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could clarify whether cannabis use is linked to more aggressive lung cancer in younger patients.
- What could go wrong
- This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may be biased due to cannabis's illegal status and frequent tobacco co-use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2021
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 59 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Any patient from 18 y.o to 59 y.o treated in one of the three above-mentioned hospitals for primary lung cancer, whatever its stage, and agreeing to participate in this research. Exclusion Criteria: * Patient denied participation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cannabis use are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre Chirurgical Marie Lannelongue
RECRUITINGLe Plessis-Robinson, 92350, France
-
Hopital Paris Saint Joseph
COMPLETEDParis, 75014, France
-
Institut Gustave Roussy
COMPLETEDVillejuif, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can rewards and remote coaching help people cut back on cannabis?
- Radiation before transplant: a new way to vaccinate against lung cancer?
- Can a short tobacco break curb cannabis cravings?
- Magnetic pulses to the brain may help lung cancer patients sleep after surgery
- Texting teens to tame risky drinking and weed use?
- Can a blood pressure medication curb cannabis cravings?